Costs of radium-223 and the pharmacy preparation 177 Lu-PSMA-I&T for metastatic castration-resistant prostate cancer in Dutch hospitals

Objective: The radiopharmaceuticals radium-223 and the pharmacy preparation 177 Lu-PSMA-I&T are reimbursed in the Netherlands for metastatic castration-resistant prostate cancer (mCRPC) treatment. Although shown to be life-prolonging in patients with mCRPC, the treatment procedures associated with these radiopharmaceuticals can be challenging for both patients and hospitals. This study investigates the costs of mCRPC treatment in Dutch hospitals for currently reimbursed radiopharmaceuticals with a demonstrated overall survival benefit. Methods: A cost model that calculated the direct medic... Mehr ...